| Biomarker ID | 838 |
| PMID | 22240788 |
| Year | 2012 |
| Biomarker | mir-107; mir-141; mir-181a-2*; mir-2110; mir-301a; mir-326; mir-432; mir-574-3p; mir-625; |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Upregulated in localised PCa: [mir-107; mir-141; mir-2110; mir-301a; mir-326; mir-432; mir-574-3p; mir-625;] Downregulated in localised PCa: [miR-181a-2* (2.69 fold)] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include (mir-107):- synapse; cellular protein modification process; protein modification process; nucleoplasm; establishment of localization in cell Pathways Include (mir-574-3p):- Pathways in cancer; Developmental Biology; regulation of nitrogen compound metabolic process; FoxO signaling pathway; Adherens junction |
| Experiment | Normal Vs localised prostate cancer |
| Type of Biomarker | Diagnostic |
| Cohort | prostate cancer cases (n=78) were selected along with (n=28) normal cases. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Cohort |
| Technical Name | mir-107, mir-141, mir-181a-2, mir-2110, mir-301a, mir-326, mir-432, mir-574-3p, mir-625 |